Table 5

Associations between antiphospholipid antibodies (aPL) and HLA-DRB1*04 and HLA-DRB1*13 among patients with systemic lupus erythematosus

Meta-analyses
N (%)OR (95% CI)p Value
DRB1*04
2GP1 IgG67 (46.5)2.66 (1.81 to 3.91)<0.00001
aCL IgG60 (41.4)1.99 (1.35 to 2.93)0.0005
aCL IgM59 (39.1)1.76 (1.20 to 2.58)0.004
aPT IgG†32 (40.0)1.69 (1.04 to 2.76)0.03
≥2aPL‡63 (44.4)2.33 (1.58 to 3.44)<0.00001
LAC§40 (47.1)2.57 (1.53 to 4.32)0.0003
DRB1*13
2GP1 IgG48 (33.3)1.69 (1.13 to 2.52)0.01
aCL IgG47 (32.4)1.60 (1.07 to 2.40)0.02
aCL IgM43 (28.5)1.25 (0.83 to 1.88)0.28
aPT IgG†28 (35.0)1.66 (1.01 to 2.75)0.05
≥2aPL‡45 (31.7)1.51 (1.00 to 2.28)0.05
LAC§28 (32.9)1.65 (0.96 to 2.86)0.06
  • N represents number of cases positive for the particular DRB1 allele and positive for the particular antibody test; (%) represents percentage of the total number positive for the antibody test (eg, for the first line, 46.5), how many patients out of all who have had aβ2GP1 IgG antibodies are DRB1*04 positive).

  • †N=593.

  • ‡N=661.

  • §Only analysed in the Stockholm group, N=363.

  • a, anti; ≥2aPL, at least two positive tests of aβ2GP-1, aCL IgG and aCL IgM; β2GP1, β2-glycoprotein 1; CL, cardolipin; Ig, immunoglobulin; LAC, lupus anticoagulant; PT, prothrombin.